Pulmonx Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered board introductions, voting on director elections, auditor ratification, and executive compensation, with all proposals approved. No shareholder questions were raised, and voting results will be filed with the SEC.
-
A minimally invasive valve system for severe emphysema has shown strong clinical results and high reimbursement rates, with global reach and a $12 billion addressable market. Recent pipeline expansion and financial restructuring aim to drive renewed growth.
-
Q1 2026 revenue declined 9% year-over-year to $20.6 million, with U.S. and international sales both down due to China registration delays, but excluding China, international markets grew 22%. Cost reductions, a new credit facility, and a focused sales strategy support reaffirmed 2026 guidance and expectations for double-digit growth exiting the year.
Fiscal Year 2025
-
Revenue grew 8% in 2025 to $90.5M, with international strength offsetting U.S. challenges. Cost restructuring and a new $60M credit facility improved financial flexibility. 2026 guidance anticipates resumed growth in H2, improved margins, and reduced cash burn.
-
Q3 2025 revenue grew 5% year-over-year to $21.5M, with international markets outpacing the U.S. Operating expenses and net loss remained high, but leadership is focused on realigning spending and improving profitability. Full-year revenue guidance is $89M-$90M.
-
International growth is robust, with double-digit gains in Europe and strong prospects in Asia. U.S. growth is challenged by hospital capacity but supported by new tools, direct-to-patient outreach, and initiatives like LungTraX and AeriSeal. Financial discipline and margin improvement remain priorities.
-
A minimally invasive valve solution for severe emphysema is targeting a $12B global market, supported by strong clinical data and broad reimbursement. U.S. growth initiatives, including direct-to-patient outreach and AI-driven patient identification, are progressing but taking longer than expected, prompting revised revenue guidance and operational efficiencies.
-
Q2 2025 revenue grew 15% year-over-year to $23.9M, led by strong international performance, while U.S. growth lagged due to capacity constraints. Full-year revenue guidance was revised down to $90–$92M, but key commercial and clinical initiatives are gaining traction.
-
A large, underserved market for minimally invasive emphysema treatment is being addressed with strong clinical evidence, broad reimbursement, and innovative technology. Growth strategies include direct-to-patient outreach, AI-driven patient identification, and global expansion.
-
A $12 billion global market exists for minimally invasive lung valve treatment, supported by strong clinical evidence and broad reimbursement. Patient acquisition is accelerating through direct advertising and AI-driven tools, with new products and geographic expansion set to drive further growth.
-
Q1 2025 revenue grew 20% year-over-year to $22.5 million, with international sales up 39% and U.S. revenue up 11%. Gross margin was 73%, and net loss was $14.4 million. Full-year guidance is reaffirmed, with U.S. growth expected to accelerate in H2 as commercial initiatives mature.
-
Strong year-over-year growth was achieved through strategic patient acquisition, workflow innovation, and international expansion. New software tools like LungTraX Connect and Detect are streamlining patient identification, while financial discipline supports confidence in reaching cash flow break even.
Fiscal Year 2024
-
Q4 and FY 2024 saw strong revenue growth (23% and 22% YoY, respectively), driven by U.S. and international expansion, new account additions, and successful commercial and clinical initiatives. 2025 guidance anticipates 16–18% constant currency growth, with margin stability and continued investment in growth drivers.
-
Leadership is accelerating a three-pronged strategy focused on high-performing centers, best practices, and awareness, supported by strong clinical data and workflow innovation. Revenue guidance is $81–$84 million (18–22% growth), with long-term targets of 20% growth and cash flow break even expected with current resources.
-
Management is executing an enhanced commercial strategy, driving strong patient engagement and international growth, while maintaining 2024 guidance and investing in workflow automation and new products. Margin expansion and profitability are expected as initiatives scale.
-
Q3 revenue grew 15% year-over-year to $20.4 million, with strong US and OUS performance and steady gross margin. Full-year revenue guidance of $81–$84 million was reiterated, supported by commercial traction, cost optimization, and positive clinical data.
-
Leadership is focused on driving utilization and workflow improvements, achieving strong growth in early 2024 and reaffirming guidance. Clinical trials and international expansion, including a major Japanese launch and AeriSeal rollout, are set to drive future growth. Ongoing workflow and technology initiatives aim to enhance patient throughput and program scale.
-
The conference highlighted a large, underserved market for minimally invasive emphysema treatment, with strong clinical data, robust financials, and a focus on workflow automation and education to drive growth. Management is confident in future expansion and continued execution.
-
Q2 2024 saw record sales of $20.8M, up 21% year-over-year, with strong U.S. growth and international expansion. Guidance for FY 2024 is reaffirmed, with revenue expected at $81–$84M and gross margin at 74–75%. Workflow automation and clinical pipeline progress support long-term growth.